Skip to main content

Main menu

  • Home
  • Content
    • Current
      • JNMT Supplement
    • Ahead of print
    • Past Issues
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
    • Institutional and Non-member
  • Authors
    • Submit to JNMT
    • Information for Authors
    • Assignment of Copyright
    • AQARA Requirements
  • Info
    • Permissions
    • Continuing Education
    • Advertisers
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Editorial Contact
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNMT
    • JNM
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine Technology
  • SNMMI
    • JNMT
    • JNM
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine Technology

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
    • Institutional and Non-member
  • Authors
    • Submit to JNMT
    • Information for Authors
    • Assignment of Copyright
    • AQARA Requirements
  • Info
    • Permissions
    • Continuing Education
    • Advertisers
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Editorial Contact
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow SNMMI on Twitter
  • Visit SNMMI on Facebook
  • Join SNMMI on LinkedIn
  • Subscribe to JNMT RSS feeds
Continuing Education

Cancer Imaging with Radiolabeled Antibodies: New Advances with Technetium-99m-Labeled Monoclonal Antibody Fab’ Fragments, Especially CEA-Scan® and Prospects for Therapy

David M. Goldenberg, Malik Juweid, Robert M. Dunn and Robert M. Sharkey
Journal of Nuclear Medicine Technology March 1997, 25 (1) 18-23;
David M. Goldenberg
Garden State Cancer Center, Center for Molecular Medicine and Immunology, Belleville, New Jersey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Malik Juweid
Garden State Cancer Center, Center for Molecular Medicine and Immunology, Belleville, New Jersey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert M. Dunn
Garden State Cancer Center, Center for Molecular Medicine and Immunology, Belleville, New Jersey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert M. Sharkey
Garden State Cancer Center, Center for Molecular Medicine and Immunology, Belleville, New Jersey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

The use of radiolabeled anticancer antibodies to detect cancer sites by external scintigraphy has had a relatively long history. With the advent of monoclonal antibodies (MAbs), which precluded the need for purifying the antibodies by laborious purification steps, there was a surge of interest and efforts to develop these reagents for both imaging and therapy applications (1). Today, many thousands of patients have received different forms and doses of MAbs for various purposes, and four MAb-based products have been licensed for manufacture and sale in the U.S. (2,3). This article describes the most recent MAb product to be approved in the U.S. for colorectal cancer imaging, including discussions of using this agent and its therapeutic counterpart in several cancer types.

  • immunoscintigraphy
  • radioimmunodetection
  • cancer
  • lymphoma
  • CEA
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine Technology: 25 (1)
Journal of Nuclear Medicine Technology
Vol. 25, Issue 1
March 1, 1997
  • Table of Contents
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine Technology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Cancer Imaging with Radiolabeled Antibodies: New Advances with Technetium-99m-Labeled Monoclonal Antibody Fab’ Fragments, Especially CEA-Scan® and Prospects for Therapy
(Your Name) has sent you a message from Journal of Nuclear Medicine Technology
(Your Name) thought you would like to see the Journal of Nuclear Medicine Technology web site.
Citation Tools
Cancer Imaging with Radiolabeled Antibodies: New Advances with Technetium-99m-Labeled Monoclonal Antibody Fab’ Fragments, Especially CEA-Scan® and Prospects for Therapy
David M. Goldenberg, Malik Juweid, Robert M. Dunn, Robert M. Sharkey
Journal of Nuclear Medicine Technology Mar 1997, 25 (1) 18-23;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Cancer Imaging with Radiolabeled Antibodies: New Advances with Technetium-99m-Labeled Monoclonal Antibody Fab’ Fragments, Especially CEA-Scan® and Prospects for Therapy
David M. Goldenberg, Malik Juweid, Robert M. Dunn, Robert M. Sharkey
Journal of Nuclear Medicine Technology Mar 1997, 25 (1) 18-23;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • Bispecific Antibody Pretargeting of Radionuclides for Immuno-Single-Photon Emission Computed Tomography and Immuno-Positron Emission Tomography Molecular Imaging: An Update
  • Antibody Pretargeting Advances Cancer Radioimmunodetection and Radioimmunotherapy
  • The Progress and Promise of Molecular Imaging Probes in Oncologic Drug Development
  • Perspectives on Cancer Therapy with Radiolabeled Monoclonal Antibodies
  • Tumor Pretargeting in Mice Using 99mTc-Labeled Morpholino, a DNA Analog
  • The Pharmacokinetic Characteristics of Glycolated Humanized Anti-Tac Fabs Are Determined by Their Isoelectric Points
  • Google Scholar

More in this TOC Section

  • Diuretic Renal Scintigraphy Protocol Considerations
  • Root Cause Analysis in Nuclear Medicine for Sentinel Events
  • SNMMI Clinical Trials Network Research Series for Technologists: Clinical Research Primer—Use of Imaging Agents in Therapeutic Drug Development and Approval
Show more Continuing Education

Similar Articles

Keywords

  • immunoscintigraphy
  • radioimmunodetection
  • cancer
  • lymphoma
  • CEA
SNMMI

© 2023 Journal of Nuclear Medicine Technology

Powered by HighWire